372 related articles for article (PubMed ID: 32652004)
1. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.
Zhou W; Zhang C; Zhang D; Peng J; Ma S; Wang X; Guan X; Li P; Li D; Jia G; Jia W
J Neurooncol; 2020 Sep; 149(3):473-487. PubMed ID: 33034841
[TBL] [Abstract][Full Text] [Related]
3. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
4. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
[TBL] [Abstract][Full Text] [Related]
6. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
Xi Z; Jones PS; Mikamoto M; Jiang X; Faje AT; Nie C; Labelle KE; Zhou Y; Miller KK; Soberman RJ; Zhang X
Front Endocrinol (Lausanne); 2021; 12():726448. PubMed ID: 34745002
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
8. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
9. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
11. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
12. Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer.
Zeng H; Huang Y; Chen L; Li H; Ma X
Int Immunopharmacol; 2020 Aug; 85():106622. PubMed ID: 32485354
[TBL] [Abstract][Full Text] [Related]
13. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
14. Immune Infiltration Landscape in Lung Squamous Cell Carcinoma Implications.
Zhao J; Bao W; Cai W
Biomed Res Int; 2020; 2020():5981870. PubMed ID: 33102584
[TBL] [Abstract][Full Text] [Related]
15. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.
Lu JQ; Adam B; Jack AS; Lam A; Broad RW; Chik CL
Endocr Pathol; 2015 Sep; 26(3):263-72. PubMed ID: 26187094
[TBL] [Abstract][Full Text] [Related]
16. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
Front Immunol; 2021; 12():693314. PubMed ID: 34177954
[TBL] [Abstract][Full Text] [Related]
17. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
18. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
[TBL] [Abstract][Full Text] [Related]
19. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
